DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20221050

Carcinogen tainted generic drugs: a matter of concern

Ankit Bhardwaj, Shoma Mukherjee

Abstract


The burden of non-communicable diseases is progressively on a rise across the globe with India contributing to a substantial quantum. Nearly 63% of total deaths in India are due to non-communicable diseases, of which 27% are due to cardiovascular diseases (CVDs). High blood pressure is among the most important risk factors for CVDs. Data (from 1950 to 2014) on hypertension in the Indian populace, revealed a high overall prevalence of 29.8% (95% CI 26.7-33.0), showing a constant rise and a marked increase in urban (33.8%) population than in rural (27.6%), 

Keywords


Generic drugs, Carcinogens, Valsartan

Full Text:

PDF

References


World Health Organization. Non-communicable diseases. Available at: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases. Accessed on 29 November 2021.

Roy A, Praveen PA, Amarchand R, Ramakrishnan L, Gupta R, Kondal D, et al. Changes in hypertension prevalence, awareness, treatment and control rates over 20 years in National Capital Region of India: results from a repeat cross-sectional study. BMJ Open. 2017;7(7):e015639.

Patni AK, Sahoo SK, Moran AE, Cohn J, Bhatia S, Maheshwari N, et al. Unmet need for hypertension treatment in India: Evidence from hypertension drugs market data. Glob Heart. 2021;16(1):26.

U. S. Food and Drug Administration. Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products. 2018. Available at: https://www.fda. gov/safety/recalls-market-withdrawals-safety-alerts wide. Accessed on 29 November 2021.

IARC 1978: International Agency for Research on Cancer working group on the Evaluation of Carcinogenic Risks to Humans. IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans: some N-nitroso compounds. IARC Monogr Eval Carcinog Risk Chem Man. 1978;17:1-349.

Carcinogens Have Infiltrated the Generic Drug Supply in the U.S. Bloomberg Businessweek. Available at: https://www.bloomberg.com/newscaogen. Accessed on 29 November 2021.

The FDA group. FDA Warning Letter & Inspection Observation Trends. Available at: https://www.thefda group.com/blog/2019-fda-warning-letter-inspection-observation-trends. Accessed on 29 December 2021.

Policy and Medicine. FDA Under Pressure to Speed Up Generic Approvals. Available at: https://www. policymed.com. Accessed on 29 November 2021.

The Conversation. The FDA’s weak drug manufacturing oversight is a potentially deadly problem. https://theconversation.com. Accessed on 29 November 2021.

Valisure-Ranitidine-FDA-Citizen-Petition- Available at: https://www.valisure.com/wp-content/ uploads FDACitizenPetitionv4.12.pdf. Accessed on 29 November 2021.

U. S. Food and Drug Administration. FDA Updates and Press Announcements on Nitrosamine in Varenicline (Chantix). 2021. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fdaalerts-health-care-professionals-and-patients-voluntary-recallvarenicline-chantix-warehouse. Accessed on 29 November 2021.

Regulatory Affairs Professionals Society. FDA addresses nitrosamines in TB drugs. 2020. Available at: https://www.raps.org/news-and-articles/news-articles/2020/8/fda-addresses-nitrosamines-in-tb-drugs. Accessed on 29 November 2021.